Article ID Journal Published Year Pages File Type
338801 Psychosomatics 2009 4 Pages PDF
Abstract

BackgroundTamoxifen is a first-generation selective estrogen-receptor modulator that has been shown to decrease recurrence and prolong survival among premenopausal women with breast cancer; however, it also results in estrogen-insufficiency symptoms, the most common being hot flushes.ObjectiveThe authors present a case in which tamoxifen apparently produced acute depression symptoms in a 34-year-old breast cancer patient.MethodAfter two aborted periods of tamoxifen treatment, the patient was started on venlafaxine as a preventive measure before tamoxifen treatment was begun again.ResultsAfter 2 months of treatment with venlafaxine, tamoxifen was initiated for a third time, with no recurrence of her previous mood symptoms.ConclusionTreatment of depression may result in better compliance with tamoxifen regimens and, thus, more favorable outcomes.

Related Topics
Health Sciences Medicine and Dentistry Psychiatry and Mental Health
Authors
, , , ,